158 related articles for article (PubMed ID: 16633504)
1. Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization.
Chisholm D
World Psychiatry; 2005 Feb; 4(1):37-44. PubMed ID: 16633504
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings.
Dziekan G; Chisholm D; Johns B; Rovira J; Hutin YJ
Bull World Health Organ; 2003; 81(4):277-85. PubMed ID: 12764494
[TBL] [Abstract][Full Text] [Related]
4. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
5. Using epidemiological data to model efficiency in reducing the burden of depression*.
Andrews G; Sanderson K; Corry J; Lapsley HM
J Ment Health Policy Econ; 2000 Dec; 3(4):175-186. PubMed ID: 11967454
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.
Chisholm D; van Ommeren M; Ayuso-Mateos JL; Saxena S
Br J Psychiatry; 2005 Dec; 187():559-67. PubMed ID: 16319409
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study.
Chisholm D; Saxena S
BMJ; 2012 Mar; 344():e609. PubMed ID: 22389339
[TBL] [Abstract][Full Text] [Related]
9. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions.
Chisholm D; Sanderson K; Ayuso-Mateos JL; Saxena S
Br J Psychiatry; 2004 May; 184():393-403. PubMed ID: 15123502
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.
Ortegón M; Lim S; Chisholm D; Mendis S
BMJ; 2012 Mar; 344():e607. PubMed ID: 22389337
[TBL] [Abstract][Full Text] [Related]
11. Prevention of violence against women and girls: A cost-effectiveness study across 6 low- and middle-income countries.
Ferrari G; Torres-Rueda S; Chirwa E; Gibbs A; Orangi S; Barasa E; Tawiah T; Dwommoh Prah RK; Hitimana R; Daviaud E; Kapapa E; Dunkle K; Heise L; Stern E; Chatterji S; Omondi B; Ogum Alangea D; Karmaliani R; Maqbool Ahmed Khuwaja H; Jewkes R; Watts C; Vassall A
PLoS Med; 2022 Mar; 19(3):e1003827. PubMed ID: 35324910
[TBL] [Abstract][Full Text] [Related]
12. Orthopaedic trauma care in Haiti: a cost-effectiveness analysis of an innovative surgical residency program.
Carlson LC; Slobogean GP; Pollak AN
Value Health; 2012; 15(6):887-93. PubMed ID: 22999139
[TBL] [Abstract][Full Text] [Related]
13. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
14. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
Cerbo AD
Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Four Tobacco Control Interventions in Mongolia.
Tuvdendorj A; Feenstra T; Buskens E
Nicotine Tob Res; 2023 Sep; 25(11):1719-1726. PubMed ID: 37478493
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis.
Chisholm D;
Epilepsia; 2005 May; 46(5):751-9. PubMed ID: 15857443
[TBL] [Abstract][Full Text] [Related]
17. The global return on investment from preventing and treating adolescent mental disorders and suicide: a modelling study.
Stelmach R; Kocher EL; Kataria I; Jackson-Morris AM; Saxena S; Nugent R
BMJ Glob Health; 2022 Jun; 7(6):. PubMed ID: 35705224
[TBL] [Abstract][Full Text] [Related]
18. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis.
Salomon JA; Carvalho N; Gutiérrez-Delgado C; Orozco R; Mancuso A; Hogan DR; Lee D; Murakami Y; Sridharan L; Medina-Mora ME; González-Pier E
BMJ; 2012 Mar; 344():e355. PubMed ID: 22389335
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
